Abstract
Understanding and being able to apply the principles of pharmacology is a key component in the treatment of patients’ medical conditions. Pharmacokinetics describes the interaction of the body upon a drug and its pathway as it moves across cell membranes. Pharmacodynamics encompasses the relationship between drug concentration and the effect within the human body. In addition to pharmacokinetics and pharmacodynamics leading to individual responses to drug therapy, exploration of the genetic influence continues to be an area of intense research. Each individual has his or her own unique genetic code and how individual genetic variations affect drug response is referred to as pharmacogenetics. While the ability to take one’s medication as directed seems like a simple concept, in actuality, adherence is complex and influenced by many factors. Medication selection and route of administration may be influenced by available formulation options and concomitant conditions. These concepts are reviewed in this chapter.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
van den Anker J. Developmental pharmacology. Dev Disabil Res Rev. 2010;16:233–8.
Buxton I, Benet L. Pharmacokinetics: The dynamics of drug absorption, distribution, action and elimination. In: Brunton K, Chabneer B, Knollman B, editors. Goodman and Gilman’s pharmacological basis of therapeutics. 12th ed. New-York: McGraw-Hill; 2011. http://0-www.accesspharmacy.com.libcat.ferris.edu/content.aspx?aID=16658148
Kearns G, Abdel-Rahman S, Alander S, Blowey D, Leeder J, Kaufmann R. Developmental pharmacology – drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157–67.
Nahata M, Taketomo C. Pediatrics. In: DiPiro J, Talbert R, Yee G, Matzke G, Wells B, Posey L, editors. Pharmacotherapy. A pathophysiological approach. 8th ed. New York: McGraw-Hill; 2011. http://0-www.accesspharmacy.com.libcat.ferris.edu/content.aspx?aID=7967222
Rempel G, Coates J. Special considerations for medication use in children with developmental disabilities. Phys Med Rehabil Clin N Am. 1999;10(2):493–509.
American Academy of Pediatrics, Committee on Drugs. Alternative routes of drug administration-advantages and disadvantages (subject review). Pediatrics. 1997;100(1):143–52.
Winter M. Clinical pharmacokinetics. In: Young L, Koda-Kimble M, editors. Applied therapeutics, the clinical use of drugs. 6th ed. Vancouver: Applied Therapeutics; 1995. p. 1–19.
Bauer L. Clinical pharmacokinetic and pharmacodynamic concepts. In: Bauer L, editor. Applied clinical pharmacokinetics. 2nd ed. New York: McGraw-Hill; 2008. http://0-www.accesspharmacy.com.libcat.ferris.edu/content.aspx?aID=3517025
Bauer L. Clinical pharamcokinetics and pharmacodynamics. In: DiPiro J, Talbert R, Yee G, Matzke G, Wells B, Posey L, editors. Pharmacotherapy, a pathophysiological approach. 8th ed. New York: McGraw-Hill; 2011. http://0-www.accesspharmacy.com.libcat.ferris.edu/content.aspx?aID=7966662
Holford N. Pharmacokinetics and pharmacodynamics: Rational dosing and the time course of drug action. In: Katzung B, Masters S, Trevor A, editors. Basic and clinical pharmacology. 12th ed. New York: McGraw-Hill; 2012. http://0-www.accesspharmacy.com.libcat.ferris.edu/content.aspx?aID=7966662
Riesenman C. Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal. Pharmacotherapy. 1995;15(6 Pt 2):84S–99.
Correia M. Drug biotransformation. In: Katzung B, Masters S, Trevor A, editors. Basic and clinical pharmacology. 12th ed. New York: McGraw-Hill; 2012. http://0-www.accesspharmacy.com.libcat.ferris.edu/content.aspx?aID=55820543
Anderson G, Lynn A. Optimizing pediatric dosing: a developmental pharmacologic approach. Pharmacotherapy. 2009;29(6):680–90.
Blumenthal D, Garrison J. Pharmacodynamics: Molecular mechanisms of drug action: Introduction. In: Brunton K, Chabneer B, Knollman B, editors. Goodman and Gilman’s pharmacological basis of therapeutics. 12th ed. New-York: McGraw-Hill; 2011. http://0-www.accesspharmacy.com.libcat.ferris.edu/content.aspx?aid=16658452
Von Zastrow M. Drug receptors and pharmacodynamics. In: Katzung B, Masters S, Trevor A, editors. Basic and clinical pharmacology. 12th ed. New York: McGraw-Hill; 2012. http://0-www.accesspharmacy.com.libcat.ferris.edu/content.aspx?aID=55820130
Galinkin J, Demmer L, Yaster M. Genetics for the pediatric anesthesiologist: a primer on congenital malformations, pharmacogenetics, and proteomics. Anesth Analg. 2010;111:1264–74.
Roden D, Altman R, Benowitz N, Flockhart D, Giacomini K, Johnson J, et al. Pharmacogenomics: challenges and opportunities. Ann Intern Med. 2006;145:749–57.
Leeder J. Pharmacogenetics and pharmacogenomics. Pediatr Clin North Am. 2001;48(3):765–81.
Evans W, McLeod H. Pharmacogenomics – drug disposition, drug targets and side effects. N Engl J Med. 2003;348(6):538–49.
Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003;348(6):529–37.
Ingleman-Sundberg M, Evans W. Unravelling the functional genomics of the human CYP2D6 gene locus. Pharmacogenetics. 2001;11:553–4.
Lexi-Comp, Inc. (Lexi-Drugs®). Lexi-Comp.
Blum M, Grant D, McBride W, Heim M, Meyer U. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol. 1990;9:193–203.
Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res. 2001;18:1400–4.
Kim R, Leake B, Choo E, Dresser G, Kubba S, Schwarz U, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001;70:189–99.
Madian A, Wheeler H, Jones R, Dolan M. Relating human genetic variation to variation in drug responses. Trends Genet. 2012;28(10):487–95.
KCNE2. Genetics Home Reference. URL: http://ghr.nlm.nih.gov/gene/KCNE2
US Food and Drug Administration, US Department of Health and Human Services. Drugs; Table of pharmacogenomic biomarkers in drug labeling. URL: http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacoge netics/ucm083378.htm
Pirmohamed M, Burnside G, Eriksson N, Jorgensen A, Toh C, Nicholson T, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013;369(24):2294–303.
Kimmel S, French B, Kasner S, Johnson J, Anderson J, Gage B, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013;369(24):2283–93.
Furie B. Do pharmacogenetics have a role in the dosing of vitamin K antagonists? N Engl J Med. 2013;369(24):2345–6.
Ma J, Lee K, Kuo G. Clinical application of pharmacogenomics. J Pharm Pract. 2012;25(4):417–27.
O’Donnell P, Bush A, Spitz J, Danahey K, Saner D, Das S, et al. The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. Nature. 2012;92(4):446–9.
Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–97.
Haynes B, McDonald H, Garg A. Helping patients follow prescribed treatment: clinical applications. JAMA. 2002;288:2880–3.
Matsui D. Current issues in pediatric medication adherence. Pediatr Drugs. 2007;9(5):283–8.
Dusing R, Lottermoser K, Mengden T. Compliance with drug therapy: new answers to an old question. Nephrol Dial Transplant. 2001;16:1317–21.
Staples B, Bravender T. Drug compliance in adolescents assessing and managing modifiable risk factors. Pediatr Drugs. 2002;4:503–13.
Winnick S, Lucas D, Hartman A, Toll D. How do you improve compliance? Pediatrics. 2005;115(6):e718–24.
Claxton A, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296–310.
Erhardt L. The essence of effective treatment and compliance is simplicity. Am J Hypertens. 1999;12(suppl):105S–10.
Ickovics J, Meade C. Adherence to HAART among patients with HIV: breakthroughs and barriers. AIDS Care. 2002;14:309–18.
Shah B, Hajjar E. Polypharmacy, adverse drug reactions and geriatric syndromes. Clin Geriatr Med. 2012;28:173–86.
Spencer D, Marshall J, Post B, Kulakodlu M, Newschaffer C, Dennen T, et al. Psychotropic medication use and polypharmacy in children with autism spectrum disorders. Pediatrics. 2013;132(5):833–40.
Hanlon J, Schmader K, Samsa G, Weinberger M, Uttech K, Lewis I, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992;45(10):1045–51.
Gokula M, Holmes H. Tools to reduce polypharmacy. Clin Geriatr Med. 2012;28:323–41.
Hovstadius B, Petersson G. Factors leading to excessive polypharmacy. Clin Geriatr Med. 2012;28:159–72.
Mula M, Trimble M. Antiepileptic drug-induced cognitive adverse effects, potential mechanisms and contributing factors. CNS Drugs. 2009;23(2):121–37.
Tutuian R. Adverse effects of drugs on the esophagus. Best Pract Res Clin Gastroenterol. 2010;24(2):91–7.
Clayden G. Management of chronic constipation. Arch Dis Child. 1992;67:340–4.
Green LB, Hurvitz EA. Cerebral palsy. Phys Med Rehabil Clin N Am. 2007;18(4):859–82.
Tilton A, Vargus-Adams J, Delgado MR. Pharmacologic treatment of spasticity in children. Semin Pediatr Neurol. 2010;17(4):261–7.
Fruen BR, Mickelson JR, Louis CF. Dantrolene inhibition of sarcoplasmic reticulum Ca2+ release by direct and specific action at skeletal muscle ryanodine receptors. J Biol Chem. 1997;272:26965–71.
Delgado MR, Hirtz D, Aisen M, Ashwal S, Fehlings DL, McLaughlin J, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2010;74(4):336–43.
Westfall T, Westfall D. Adrenergic agonists and antagonists. In: Brunton K, Chabneer B, Knollman B, editors. Goodman and Gilman’s pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill; 2011. http://0-accesspharmacy.mhmedical.com.libcat.ferris.edu/content.aspx?bookid=374%26sectionid=41266218
Mihic S, Harris A. Hypnotics and sedatives. In: Brunton K, Chabneer B, Knollman B, editors. Goodman and Gilman’s pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill; 2011. http://0-accesspharmacy.mhmedical.com.libcat.ferris.edu/content.aspx?bookid=374§ionid=41266223
Meyer J. Pharmacotherapy of psychosis and mania. In: Brunton K, Chabneer B, Knollman B, editors. Goodman and Gilman’s pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill; 2011. http://0-accesspharmacy.mhmedical.com.libcat.ferris.edu/content.aspx?bookid=374§ionid=41266222
McNamara J. Pharmacotherapy of epilepsies. In: Brunton K, Chabneer B, Knollman B, editors. Goodman and Gilman’s pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011. URL: http://0-accesspharmacy.mhmedical.com.libcat.ferris.edu/content.aspx?bookid=374§ionid=41266227
Food and Drug Administration. URL: www.fda.gov
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Feucht, C., Patel, D.R., Bovid, K.M. (2016). Principles of Pharmacology. In: Rubin, I.L., Merrick, J., Greydanus, D.E., Patel, D.R. (eds) Health Care for People with Intellectual and Developmental Disabilities across the Lifespan. Springer, Cham. https://doi.org/10.1007/978-3-319-18096-0_141
Download citation
DOI: https://doi.org/10.1007/978-3-319-18096-0_141
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-18095-3
Online ISBN: 978-3-319-18096-0
eBook Packages: MedicineMedicine (R0)